- Home
- AKA vs ZURA Comparison
AKA vs ZURA Comparison
Compare AKA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- ZURA
- Stock Information
- Founded
- AKA 2018
- ZURA 2022
- Country
- AKA United States
- ZURA United States
- Employees
- AKA N/A
- ZURA N/A
- Industry
- AKA Catalog/Specialty Distribution
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AKA Consumer Discretionary
- ZURA Health Care
- Exchange
- AKA Nasdaq
- ZURA Nasdaq
- Market Cap
- AKA 110.4M
- ZURA 69.9M
- IPO Year
- AKA 2021
- ZURA N/A
- Fundamental
- Price
- AKA $11.08
- ZURA $1.31
- Analyst Decision
- AKA Buy
- ZURA Buy
- Analyst Count
- AKA 4
- ZURA 7
- Target Price
- AKA $22.50
- ZURA $14.33
- AVG Volume (30 Days)
- AKA 8.6K
- ZURA 708.2K
- Earning Date
- AKA 08-06-2025
- ZURA 08-08-2025
- Dividend Yield
- AKA N/A
- ZURA N/A
- EPS Growth
- AKA N/A
- ZURA N/A
- EPS
- AKA N/A
- ZURA N/A
- Revenue
- AKA $586,514,000.00
- ZURA N/A
- Revenue This Year
- AKA $6.60
- ZURA N/A
- Revenue Next Year
- AKA $4.14
- ZURA N/A
- P/E Ratio
- AKA N/A
- ZURA N/A
- Revenue Growth
- AKA 8.09
- ZURA N/A
- 52 Week Low
- AKA $7.00
- ZURA $0.97
- 52 Week High
- AKA $32.25
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- AKA 45.23
- ZURA 59.63
- Support Level
- AKA $10.71
- ZURA $1.00
- Resistance Level
- AKA $11.59
- ZURA $1.45
- Average True Range (ATR)
- AKA 0.71
- ZURA 0.10
- MACD
- AKA -0.05
- ZURA 0.03
- Stochastic Oscillator
- AKA 33.20
- ZURA 68.89
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.